Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Myositis
Do you screen for cardiac disease in patients with dermatomyositis in the absence of symptoms?
Related Questions
When do you consider the use of JAK inhibitors for cutaneous manifestations of myositis?
How do you approach weakly positive PL-7 antibody in a patient who initially presented with muscle weakness, rhabdomyolysis and non specific muscular edema on MRI that resolved with IV fluids?
How do you interpret negative HMGCR antibody test results in a patient with necrotizing myopathy who has already been on treatment with steroids and whose CK has normalized?
In light of the RECITAL study, would rituximab be a reasonable choice in a patient with PL-12 antibodies, rapidly progressive pulmonary disease with organizing pneumonia on biopsy?
Would you consider adding rituximab to a patient with SLE (lupus anticoagulant positive but no history of thrombotic events) and organizing pneumonia (on azathioprine, prednisone, and hydroxychloroquine) who now also has polymyositis?
What would be your approach to a patient with Scleroderma/Myositis overlap syndrome (+anti-Ku) and active inflammatory eye disease despite high dose mycophenolate?
Do you recommend discontinuing IVIG for a newly diagnosed HMGCR+ statin induced necrotizing myopathy who developed a recent brachial DVT?
How would you approach a patient with elevated CPK in the 500-1000 range with no weakness on exam or myositis on MRI but with positive HMGCoA ab?
How do you counsel patients with non-statin associated inflammatory myopathies about statin use?
Would you avoid combining JAK inhibitors with IVIG given the risk of thromboembolism?
